

Zachary Scott Wallace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435564/publications.pdf>

Version: 2024-02-01

126
papers

8,660
citations

81900
39
h-index

48315
88
g-index

131
all docs

131
docs citations

131
times ranked

7199
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
2	Rituximab for IgG4-related disease: a prospective, open-label trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1171-1177.	0.9	533
3	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
4	IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 2466-2475.	5.6	463
5	Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 190-195.	0.9	409
6	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 77-87.	0.9	390
7	Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 825-838.	2.9	306
8	De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 679-687.	2.9	302
9	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 7-19.	5.6	292
10	Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 406-412.	0.9	248
11	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US "hot spot". <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1156-1162.	0.9	217
12	Ophthalmic manifestations of IgG4-related disease: Single-center experience and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 806-817.	3.4	182
13	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
14	IgG4-Related Disease and Hypertrophic Pachymeningitis. <i>Medicine (United States)</i> , 2013, 92, 206-216.	1.0	155
15	Predictors of disease relapse in IgG4-related disease following rituximab. <i>Rheumatology</i> , 2016, 55, 1000-1008.	1.9	151
16	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
17	IgG4-Related Systemic Disease as a Cause of "Idiopathic" Orbital Inflammation, Including Orbital Myositis, and Trigeminal Nerve Involvement. <i>Survey of Ophthalmology</i> , 2012, 57, 26-33.	4.0	144
18	Large vessel involvement by IgG4-related disease. <i>Medicine (United States)</i> , 2016, 95, e3344.	1.0	132

#	ARTICLE	IF	CITATIONS
19	Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. Journal of Allergy and Clinical Immunology, 2019, 143, 736-745.e6.	2.9	123
20	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	3.8	121
21	B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Annals of the Rheumatic Diseases, 2015, 74, 2236-2243.	0.9	120
22	COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis and Rheumatology, 2021, 73, 914-920.	5.6	117
23	<scp>SARS</scp>â€“<scp>CoV</scp>â€² Infection and <scp>COVID</scp>â€²19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Metaâ€Analysis. Arthritis and Rheumatology, 2022, 74, 766-775.	5.6	117
24	An International Multispecialty Validation Study of the IgG4â€Related Disease Responder Index. Arthritis Care and Research, 2018, 70, 1671-1678.	3.4	103
25	Association of IgG4â€Related Disease With History of Malignancy. Arthritis and Rheumatology, 2016, 68, 2283-2289.	5.6	90
26	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86
27	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Annals of the Rheumatic Diseases, 2021, 80, 660-666.	0.9	74
28	All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology, 2020, 59, 2308-2315.	1.9	71
29	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 289-291.	0.9	69
30	Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis and Rheumatology, 2021, 73, 374-380.	5.6	66
31	Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney International Reports, 2018, 3, 394-402.	0.8	61
32	Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatology, The, 2021, 3, e131-e137.	3.9	61
33	Improved survival in granulomatosis with polyangiitis: A general population-based study. Seminars in Arthritis and Rheumatism, 2016, 45, 483-489.	3.4	55
34	Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 737-743.e3.	3.8	54
35	Management of ANCA associated vasculitis. BMJ, The, 2020, 368, m421.	6.0	54
36	CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. Journal of Allergy and Clinical Immunology, 2021, 147, 368-382.	2.9	53

#	ARTICLE	IF	CITATIONS
37	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. Arthritis and Rheumatology, 2021, 73, 36-47.	5.6	52
38	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
39	Renal Transplantation and Survival Among Patients With Lupus Nephritis. Annals of Internal Medicine, 2019, 170, 240.	3.9	48
40	Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies. Arthritis and Rheumatology, 2017, 69, 1722-1732.	5.6	46
41	Immunoglobulin G4-related Disease. Clinics in Chest Medicine, 2019, 40, 583-597.	2.1	42
42	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e707-e714.	3.9	40
43	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	1.9	40
44	An update on IgG4-related disease. Current Opinion in Rheumatology, 2015, 27, 83-90.	4.3	39
45	Lymphomas in IgG4-related disease: clinicopathologic features in a Western population. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 839-852.	2.8	39
46	All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis and Rheumatology, 2019, 71, 403-410.	5.6	38
47	Disease Severity Linked to Increase in Autoantibody Diversity in IgG4-Related Disease. Arthritis and Rheumatology, 2020, 72, 687-693.	5.6	38
48	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	3.9	38
49	SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Annals of the Rheumatic Diseases, 2021, 80, 817-819.	0.9	37
50	DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Seminars in Arthritis and Rheumatism, 2022, 55, 152025.	3.4	36
51	The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance. Rheumatology, 2020, 59, 1204-1206.	1.9	34
52	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	3.8	34
53	Nationwide Trends in Hospitalizations and In-Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). Arthritis Care and Research, 2017, 69, 915-921.	3.4	32
54	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. Rheumatology, 2021, 60, 353-358.	1.9	32

#	ARTICLE	IF	CITATIONS
55	COVID-19 and rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2021, 33, 255-261.	4.3	32
56	Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. <i>Medicine (United States)</i> , 2018, 97, e12631.	1.0	31
57	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e638-e647.	3.9	30
58	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
59	Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?. <i>Frontiers in Immunology</i> , 2019, 10, 2855.	4.8	28
60	Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA Internal Medicine</i> , 2020, 180, 870.	5.1	28
61	Coronavirus Disease 2019 Outcomes Among Recipients of <scp>Anti-CD20</scp> Monoclonal Antibodies for <scp>Immune-Mediated</scp> Diseases: A Comparative Cohort Study. <i>ACR Open Rheumatology</i> , 2022, 4, 238-246.	2.1	27
62	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , 2021, 13, 35.	8.2	26
63	Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 347-354.	5.6	25
64	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	5.6	23
65	COVID-19 severity in asthma patients: a multi-center matched cohort study. <i>Journal of Asthma</i> , 2022, 59, 442-450.	1.7	22
66	Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 288-292.	3.4	21
67	Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 190-195.e2.	1.0	21
68	Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study. <i>Arthritis Care and Research</i> , 2020, 72, 1543-1549.	3.4	20
69	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. <i>Pancreatology</i> , 2021, 21, 1395-1401.	1.1	20
70	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	3.4	19
71	Atypical IgG4+ Plasmacytic Proliferations and Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 215-235.	0.7	18
72	The association of smoking with immunoglobulin G4-related disease: a case-control study. <i>Rheumatology</i> , 2021, 60, 5310-5317.	1.9	18

#	ARTICLE	IF	CITATIONS
73	The Association Between Physician Gender and Career Advancement Among Academic Rheumatologists in the United States. <i>Arthritis and Rheumatology</i> , 2021, 73, 168-172.	5.6	17
74	Incident systemic rheumatic disease following COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e402-e404.	3.9	17
75	Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study. <i>Lancet Rheumatology</i> , The, 2022, 4, e105-e112.	3.9	16
76	COVID-19 and Disease-Modifying Anti-rheumatic Drugs. <i>Current Rheumatology Reports</i> , 2021, 23, 28.	4.7	15
77	The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.3-2.	0.9	14
78	Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1333-1338.	0.9	13
79	Lifetime Allergy Symptoms in <scp>IgG4â€Related</scp> Disease: A Caseâ€Control Study. <i>Arthritis Care and Research</i> , 2022, 74, 1188-1195.	3.4	13
80	Barriers and Facilitators of Mentoring for Trainees and Early Career Investigators in Rheumatology Research: Current State, Identification of Needs, and Road Map to an Interâ€Institutional Adult Rheumatology Mentoring Program. <i>Arthritis Care and Research</i> , 2018, 70, 445-453.	3.4	12
81	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	3.4	11
82	Improving Mortality in Endâ€Stage Renal Disease Due to Granulomatosis With Polyangiitis (Wegener's) From 1995 to 2014: Data From the United States Renal Data System. <i>Arthritis Care and Research</i> , 2018, 70, 1495-1500.	3.4	10
83	Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. <i>ACR Open Rheumatology</i> , 2020, 2, 261-268.	2.1	10
84	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. <i>Global Rheumatology</i> , 0, , .	0.0	10
85	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88.	0.6	10
86	Phospholipase A2 receptorâ€associated membranous nephropathy in a patient with IgG4-related disease. <i>Medicine (United States)</i> , 2019, 98, e15616.	1.0	9
87	Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid. <i>Arthritis and Rheumatology</i> , 2020, 72, 234-241.	5.6	9
88	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
89	Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. <i>ACR Open Rheumatology</i> , 2021, 3, 834-841.	2.1	9
90	Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy. <i>RMD Open</i> , 2022, 8, e002082.	3.8	9

#	ARTICLE	IF	CITATIONS
91	Response to: “Correspondence on “SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease” by C<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e131-e131.	0.9	8
92	Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning–Derived Chest Radiograph Scores. Arthritis Care and Research, 2023, 75, 657-666.	3.4	8
93	Prostate and pancreas involvement are linked in IgG4-related disease. Seminars in Arthritis and Rheumatism, 2020, 50, 1245-1251.	3.4	7
94	Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. JAMA Internal Medicine, 2021, 181, 284.	5.1	7
95	Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by van Vollenhoven<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e178-e178.	0.9	7
96	The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7
97	Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. Rheumatology, 2022, 61, SI151-SI156.	1.9	7
98	The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. Annals of the Rheumatic Diseases, 2022, 81, 1438-1445.	0.9	7
99	Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Current Opinion in Rheumatology, 2021, 33, 412-418.	4.3	6
100	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. ACR Open Rheumatology, 2022, 4, 128-133.	2.1	6
101	ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry. Journal of Rheumatology, 2021, 48, 1060-1064.	2.0	5
102	Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study. Seminars in Arthritis and Rheumatism, 2021, 51, 150-157.	3.4	5
103	Kidney Transplantation and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis: A Nationwide Cohort Study. Arthritis Care and Research, 2022, 74, 1829-1834.	3.4	5
104	Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. Journal of Rheumatology, 2022, 49, 104-109.	2.0	5
105	Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis. Annals of the Rheumatic Diseases, 2020, 79, e40-e40.	0.9	4
106	Response to: “COVID-19 in patients with rheumatological diseases treated with Anti-TNF” by Brito et al and “Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China –hot spot” versus in US –hot spot”: similarities and differences” by Zhao et al. Annals of the Rheumatic Diseases, 2021, 80, e64-e64.	0.9	4
107	Association of renal transplantation with reduced risk of myocardial infarction and ischemic stroke in ANCA-associated vasculitis: An observational cohort study. Seminars in Arthritis and Rheumatism, 2021, 51, 1180-1185.	3.4	4
108	Therapeutic Drug Monitoring for Immune-Mediated Inflammatory Diseases. JAMA - Journal of the American Medical Association, 2021, 326, 2370.	7.4	4

#	ARTICLE	IF	CITATIONS
109	Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality. Rheumatology, 2023, 62, 716-725.	1.9	4
110	Response to: “Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4â€¦years” by Yamamoto et al. Annals of the Rheumatic Diseases, 2015, 74, e47-e47.	0.9	3
111	Response to: “COVID-19 in patients with rheumatic diseases: what is the real mortality risk?” by Marques et al. Annals of the Rheumatic Diseases, 2022, 81, e135-e135.	0.9	3
112	Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al. Annals of the Rheumatic Diseases, 2023, 82, e158-e158.	0.9	3
113	Derivation and Validation of Algorithms to Identify Patients With Immunoglobulinâ€•G4â€•Related Disease Using Administrative Claims Data. ACR Open Rheumatology, 2022, , .	2.1	3
114	Case 15-2017 “A 27-Year-Old Woman with Anemia, Thrombocytosis, and Skin Lesions after Travel Abroad. New England Journal of Medicine, 2017, 376, 1973-1981.	27.0	2
115	171.â€•CARDIOVASCULAR DISEASE IS THE MOST COMMON CAUSE OF DEATH IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	1.9	2
116	Validation of Antineutrophil Cytoplasmic Antibodyâ€•Associated Vasculitis as the Cause of <scp>Endâ€•Stage</scp> Renal Disease in the <scp>US</scp> Renal Data System. ACR Open Rheumatology, 2022, 4, 8-12.	2.1	2
117	Case 20-2018: A 64-Year-Old Man with Fever, Arthralgias, and Testicular Pain. New England Journal of Medicine, 2018, 378, 2518-2529.	27.0	1
118	An 80â€•Yearâ€•Old Man With Fevers, Altered Mental Status, and Joint Effusions. Arthritis Care and Research, 2020, 72, 293-300.	3.4	1
119	Response to: “Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors” by Jovani et al. Annals of the Rheumatic Diseases, 2022, 81, e132-e132.	0.9	1
120	Management of primary vasculitides with biologic and novel small molecule medications. Current Opinion in Rheumatology, 2021, 33, 8-14.	4.3	1
121	The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. Rheumatology and Therapy, 2022, 9, 497-508.	2.3	1
122	Case 37-2021: A 60-Year-Old Man with Fevers, Fatigue, Arthralgias, a Mouth Ulcer, and a Rash. New England Journal of Medicine, 2021, 385, 2282-2293.	27.0	1
123	172.â€•THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	1.9	0
124	157â€•...Contemporary prescription opioid use among patients with systemic lupus erythematosus: a population-based cohort study. , 2019, , .		0
125	Reply. Arthritis and Rheumatology, 2020, 72, 201-202.	5.6	0
126	Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases. Lancet Rheumatology, The, 2022, , .	3.9	0